RxDoctor Payments Data

Guy Rogers, PA

Physician Assistant · Sayre, PANPI 1871567545

Payments from drug & device makers

$10,765in general payments, 2019–2025

Across 343 payments — averaging $31.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Novartis$696
  • Johnson & Johnson$696
  • Pfizer$690
  • AstraZeneca$538
  • Edwards Lifesciences$512
  • plus $2K from 16 others

What the payments were for

  • Speaking & faculty fees$7507%
  • Travel & lodging$2,40222%
  • Food & beverage$7,61371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,765 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,193
Medicare patients
317
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$233,090
EntrestoSacubitril/Valsartan106$145,577
BrilintaTicagrelor127$71,319
XareltoRivaroxaban65$69,588
JardianceEmpagliflozin22$26,426
Repatha SureclickEvolocumab19$15,856
Praluent PenAlirocumab17$8,451
VascepaIcosapent Ethyl21$7,149
Metoprolol Succinate381$6,145
Atorvastatin Calcium251$4,271
Rosuvastatin Calcium266$3,758
Labetalol Hcl61$3,647
Dabigatran EtexilateDabigatran Etexilate Mesylate14$2,326
Prasugrel Hcl49$1,577
Torsemide108$1,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$690$233,090194 claims
NovartisEntresto$696$145,577106 claims
AstraZenecaBrilinta$538$71,319127 claims
Johnson & JohnsonXarelto$696$69,58865 claims
Boehringer IngelheimJardiance$386$26,42622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →